Related references
Note: Only part of the references are listed.Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma
Elizabeth D. Thompson et al.
GUT (2017)
Combination cancer immunotherapies tailored to the tumour microenvironment
Mark J. Smyth et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases
Mark J. Osborn et al.
MOLECULAR THERAPY (2016)
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
Shu Su et al.
SCIENTIFIC REPORTS (2016)
Deregulation of Immune Response Genes in Patients With Epstein-Barr Virus-Associated Gastric Cancer and Outcomes
Sun Young Kim et al.
GASTROENTEROLOGY (2015)
Update on Epstein-Barr virus and gastric cancer
Aya Shinozaki-Ushiku et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Inhibition of HIV-1 infection of primary CD4(+) T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9
Chang Li et al.
JOURNAL OF GENERAL VIROLOGY (2015)
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
Andrew B. Sharabi et al.
LANCET ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro
Lina Quan et al.
PLOS ONE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Efficient Gene Editing in Primary Human T Cells
Yvonne Y. Chen
TRENDS IN IMMUNOLOGY (2015)
The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy
Yanping Xiao et al.
CANCER DISCOVERY (2015)
Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
Andrew B. Sharabi et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Genomic assays for Epstein-Barr virus-positive gastric adenocarcinoma
Margaret L. Gulley
EXPERIMENTAL AND MOLECULAR MEDICINE (2015)
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Simon J. Dovedi et al.
CANCER RESEARCH (2014)
Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer
Jingying Hou et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2014)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
Wenfeng Fang et al.
ONCOTARGET (2014)
Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications
Zhixue Zheng et al.
CHINESE JOURNAL OF CANCER RESEARCH (2014)
Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+/M1 Phenotype that Orchestrates Effective T Cell Immunotherapy
Felix Klug et al.
CANCER CELL (2013)
PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Benjamin J. Chen et al.
CLINICAL CANCER RESEARCH (2013)
Increased PD-1 expression on CD4+and CD8+T cells is involved in immune evasion in gastric cancer
Hiroaki Saito et al.
JOURNAL OF SURGICAL ONCOLOGY (2013)
Cas9 as a versatile tool for engineering biology
Prashant Mali et al.
NATURE METHODS (2013)
Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies
Angharad Lloyd et al.
FRONTIERS IN IMMUNOLOGY (2013)
A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity
Martin Jinek et al.
SCIENCE (2012)
Epstein-Barr Virus (EBV)-associated Gastric Carcinoma
Hisashi Iizasa et al.
VIRUSES-BASEL (2012)
Contribution of Epstein-Barr Virus Infection to Chemoresistance of Gastric Carcinoma Cells to 5-Fluorouracil
Jung Seon Seo et al.
ARCHIVES OF PHARMACAL RESEARCH (2011)
T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract
Binfeng Lu et al.
IMMUNOLOGIC RESEARCH (2011)
Association between Epstein-Barr virus infection and chemoresistance to docetaxel in gastric carcinoma
Hee Jong Shin et al.
MOLECULES AND CELLS (2011)
Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs
Raymond M. Wong et al.
INTERNATIONAL IMMUNOLOGY (2007)
PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies
J. Sun et al.
TISSUE ANTIGENS (2007)
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance
Changping Wu et al.
ACTA HISTOCHEMICA (2006)
Expression of Epstein-Barr virus genes in EBV-associated gastric carcinomas
Bing Luo et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2005)
Penetration of intra-arterially administered vincristine in experimental brain tumor
FM Boyle et al.
NEURO-ONCOLOGY (2004)
In situ expression and significance of B7 costimulatory molecules within tissues of human gastric carcinoma
XL Chen et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2003)
The importance of exogenous antigen in priming the human CD8+ T cell response:: Lessons from the EBV nuclear antigen EBNA1
N Blake et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
